Proactive Investors - Run By Investors For Investors

Avacta teams up with Selexis to develop Chinese hamster ovary cell line

On the tie-up with Selexis, Avacta chief executive Alastair Smith said the company's new partner provided “the technology and know-how” to develop the required cell lines for the planned first-in-human study
drug trial graphic
The company said it expects to make an investigational new drug/clinical trial application by the end of next year

Avacta Group PLC (LON:AVCT) has selected a company called Selexis to help develop the Chinese hamster ovary cell line that will be used to manufacture the company’s first Affimer clinical candidate.

Affimers are essentially small, engineered proteins capable of binding specific molecular targets, in a similar way to antibodies.

This binding property can be used to target cancer cells in the human body and make those cells vulnerable to attack from the body’s own immune system.

Many existing immuno-oncology therapies use an antibody to target cancer, but Affimers have several innovative features which potentially make them a better tool for therapeutic applications.

They are smaller, quicker to manufacture and easier to format, but they maintain antibody-like biologic activity when binding a target.

Last week Avacta said it had has selected the cancer drug candidate that it will take into first-in-human clinical trials.

Affimer molecule AVA004 was picked because of its “excellent” properties in lab test. It will be developed as a PD-L1, one of a breed of cancer drugs known as checkpoint inhibitors.

AVA004 was shown to be as good as three of the current PD-L1 drugs already on the market in lab tests.

On the tie-up with Selexis, Avacta chief executive Alastair Smith said the company's new partner provided “the technology and know-how” to develop the required cell line for the planned first-in-human study.

“These cell lines are the essential basis of clinical manufacturing of AVA004 and this partnership supports Avacta's strategy to demonstrate safety and tolerability of the Affimer platform in humans with a planned investigational new drug/clinical trial by the end of 2020,” Smith added.

View full AVCT profile View Profile

Avacta Group PLC Timeline

CN Research
April 09 2019

Related Articles

blood
June 21 2019
Belgium-based company’s Nu.Q test screens for colorectal and prostate cancers, and may have the potential to detect ovarian disease endometriosis
human kidneys
May 06 2019
The Danish company is seeking FDA approval of the test for use in both adults and children
1550762209_shutterstock_291998651.jpg
February 21 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use